Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
Xilio Therapeutics dosed the first patient in its Phase 1/2 trial of XTX501, a PD-1/masked IL-2 bispecific, in patients with metastatic NSCLC previously treated with anti-PD(L)-1 therapy. The first-in-human, open-label trial is enrolling at multiple U.S. sites (NCT07688577), and the company will present a trial-in-progress poster at the SITC Annual Meeting November 4-8, 2026.
Key figures
- Drug Name
- XTX501
- Phase Of Trial
- Phase 1/2
- Indication
- metastatic NSCLC post anti-PD(L)-1
- Trial identifier
- NCT07688577
- Initial data timing
- Q4 2027
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.